Cannabis company Creso Pharma (OTCMKTS: COPHF)’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early findings on its ongoing Phase 2 clinical trial assessing the efficacy of psilocybin on treatment-resistant PTSD. 

The single-arm, open-lab study tests the efficacy of Halucenex’s synthetic psilocybin aqueous solution, Lucenex, in both 10mg and 25mg formats on severe PTSD symptoms of 20 patients.

The psychedelic is being administered in separate sessions in a microdose and macro dose format. 

Severe PTSD symptoms measured are depression and anxiety. Other measures include sleep time, addiction severity, suicidal ideation, general psychological symptoms such as pain and interpersonal relationships, overall functioning, work capacity, and physiological measures such as weight and blood pressure. 

Of the total participants, two patients to date …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.